Biogen Inc.
BIIB
$184.02
-$4.03-2.14%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.22% | 4.77% | 3.36% | 1.59% | -1.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.22% | 4.77% | 3.36% | 1.59% | -1.62% |
| Cost of Revenue | -4.13% | -3.43% | -2.88% | 12.41% | 1.95% |
| Gross Profit | 4.53% | 7.91% | 5.82% | -1.93% | -2.86% |
| SG&A Expenses | 1.98% | 4.96% | -3.03% | -3.74% | -4.62% |
| Depreciation & Amortization | 31.20% | 38.14% | 52.13% | 56.31% | 60.64% |
| Other Operating Expenses | 14.07% | 10.25% | 11.47% | 8.62% | 16.27% |
| Total Operating Expenses | -0.61% | 1.18% | -2.97% | -6.06% | -10.60% |
| Operating Income | 10.07% | 14.90% | 25.19% | 30.93% | 36.30% |
| Income Before Tax | -18.34% | -0.11% | 36.82% | 32.43% | 46.98% |
| Income Tax Expenses | -3.73% | 1.30% | 70.95% | 75.06% | 102.37% |
| Earnings from Continuing Operations | -20.79% | -0.37% | 32.21% | 26.73% | 40.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.79% | -0.41% | 32.10% | 26.80% | 40.57% |
| EBIT | 10.07% | 14.90% | 25.19% | 30.93% | 36.30% |
| EBITDA | 11.27% | 16.19% | 26.24% | 31.52% | 36.25% |
| EPS Basic | -21.28% | -1.04% | 31.43% | 26.09% | 39.70% |
| Normalized Basic EPS | 8.66% | 17.82% | 24.19% | 25.68% | 24.34% |
| EPS Diluted | -21.24% | -1.01% | 31.58% | 26.31% | 40.06% |
| Normalized Diluted EPS | 8.74% | 17.93% | 24.29% | 25.91% | 24.54% |
| Average Basic Shares Outstanding | 0.64% | 0.60% | 0.60% | 0.60% | 0.59% |
| Average Diluted Shares Outstanding | 0.53% | 0.50% | 0.55% | 0.48% | 0.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |